Drugs
Viventia Biotech Inc. has received clearance from Health Canada to initiate a phase 2 study evaluating Proxinium for the treatment of patients with chemotherapy-refractory recurrent head and neck cancer. Following the FDA's clearance in October 2005, the company is set to initiate the trial by the end of
Drugs
Researchers at the University of Texas M.D. Anderson Cancer Center have found that curcumin, the main ingredient of turmeric, inhibits metastasis to the lungs of mice with breast cancer. The study, published in the journal Clinical Cancer Research, reports that curcumin appears to shut down a protein active in
Drugs
Dr. Bernard Escudier, Head of Immunotherapy and Innovative Therapy Unit at the Gustave-Roussy Institute in Paris, presented interim results from the Phase III trial of Nexavar in patients with advanced renal cell carcinoma (RCC) at the 13th European Cancer Conference (ECCO). The study showed a significant improvement in survival for
Drugs
Researchers in the United States, South Korea, and Netherlands have made significant strides in cancer therapy research, with breakthroughs in the treatment of various types of cancer, including nasopharyngeal carcinoma, hepatocellular carcinoma, and colorectal cancer. Recent studies have focused on the development of new agents and therapies that target specific
Drugs
Japanese researchers reported the efficacy of postoperative intratumoral chemotherapy with bleomycin for craniopharyngiomas in a 1985 study. However, the treatment had not been widely implemented until a long-term outcome and reconsideration of the treatment were conducted. H. Takahashi and colleagues from Nippon Medical School investigated the effectiveness of local bleomycin
Drugs
A new phase III study of the investigational vaccine Gardasil, developed by Merck & Co., Inc., has shown a 100% effectiveness in preventing high-grade cervical pre-cancers and non-invasive cervical cancers associated with human papillomavirus (HPV) types 16 and 18. The study, titled FUTURE II, involved over 12,000 women from
Cancer treatment
Callisto Pharmaceuticals, Inc. has released a corporate video showcasing its lead anti-cancer drug candidates, Atiprimod and Annamycin. The video, featuring CEO Dr. Gary S. Jacob, explains the company's drug development programs and highlights the anticipated medical and marketplace advantages of its two drug candidates. Atiprimod and Annamycin are
Cancer treatment
Bayer Pharmaceuticals Corp. has submitted a Marketing Authorization Application to the European Medicines Agency for the approval of sorafenib in the treatment of advanced Renal Cell Carcinoma, also known as kidney cancer. This application is part of the companies' efforts to make the anti-cancer drug candidate available to doctors
Drugs
MIV Therapeutics, a developer of next-generation biocompatible stent coatings and drug delivery technologies, has announced the filing of landmark US and international Patent Cooperation Treaty (PCT) patent applications for its advanced "Smart" drug delivery systems. The cutting-edge technology combines nanotechnology and pharmaceutical solutions to produce nano-to-micro sized particles
Drugs
ImClone Systems Incorporated and Bristol-Myers Squibb announced that ImClone Systems has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for approval of ERBITUX in the treatment of squamous cell carcinoma of the head and neck. The application seeks marketing approval for the use of
Drugs
Researchers in Australia, Germany, and the United States are making significant strides in understanding and treating lymphoma, a type of cancer that affects the immune system. Three recent studies have shed light on the potential of rituximab, a monoclonal antibody therapy, in combination with other treatments. While progress is being
Drugs
Researchers in the United States and Japan have reported significant advances in cancer therapy by targeting angiogenesis, a crucial process in tumor growth and metastasis. Their studies demonstrate the effectiveness of new approaches in inhibiting vascular endothelial growth factor (VEGF) and its receptors, as well as other signaling pathways involved
